인플루엔자 진단 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Influenza Diagnostics Market - Scope of Report

TMR's report on the global influenza diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global influenza diagnostics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global influenza diagnostics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the influenza diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global influenza diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global influenza diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global influenza diagnostics market.

The report delves into the competitive landscape of the global influenza diagnostics market. Key players operating in the global influenza diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global influenza diagnostics market profiled in this report.

Key Questions Answered in Global influenza diagnostics Market Report:

• What is the sales/revenue generated by influenza diagnostics across all regions during the forecast period?
• What are the opportunities in the global influenza diagnostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Influenza Diagnostics Market - Research Objectives and Research Approach

The comprehensive report on the global influenza diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global influenza diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global influenza diagnostics market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Influenza Diagnostics Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Influenza Diagnostics Market Analysis and Forecast, 2017-2031
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Disease Epidemiology
• 5.2. Reimbursement Scenario
• 5.3. COVID-19 Pandemic Impact on Industry

6. Global Influenza Diagnostics Market Analysis and Forecast, by Flu Virus Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast, by Flu Virus Type, 2017-2031
  • 6.3.1. Type A
  • 6.3.2. Type B
• 6.4. Market Attractiveness Analysis, by Flu Virus Type

7. Global Influenza Diagnostics Market Analysis and Forecast, by Test Type

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast, by Test Type, 2017-2031
  • 7.3.1. RT-PCR Tests
  • 7.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
  • 7.3.3. Viral Culture
  • 7.3.4. Immunofluorescence Assays
  • 7.3.5. Serological Tests
  • 7.3.6. Others (LAMP, SAMBA, etc.)
• 7.4. Market Attractiveness Analysis, by Test Type

8. Global Influenza Diagnostics Market Analysis and Forecast, by Product Type

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast, by Product Type, 2017-2031
  • 8.3.1. Kits & Reagents
  • 8.3.2. Instrument
  • 8.3.3. Others
• 8.4. Market Attractiveness Analysis, by Product Type

9. Global Influenza Diagnostics Market Analysis and Forecast, by End-user

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast, by End-user, 2017-2031
  • 9.3.1. Hospitals
  • 9.3.2. Diagnostic Centers
  • 9.3.3. Others (academics & research institutes, etc.)
• 9.4. Market Attractiveness Analysis, by End-user

10. Global Influenza Diagnostics Market Analysis and Forecast, by Region

• 10.1. Key Findings
• 10.2. Market Value Forecast, by Region
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness Analysis, by Region

11. North America Influenza Diagnostics Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Flu Virus Type, 2017-2031
  • 11.2.1. Type A
  • 11.2.2. Type B
• 11.3. Market Value Forecast, by Test Type, 2017-2031
  • 11.3.1. RT-PCR Tests
  • 11.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
  • 11.3.3. Viral Culture
  • 11.3.4. Immunofluorescence Assays
  • 11.3.5. Serological Tests
  • 11.3.6. Others (LAMP, SAMBA, etc.)
• 11.4. Market Value Forecast, by Product Type, 2017-2031
  • 11.4.1. Kits & Reagents
  • 11.4.2. Instrument
  • 11.4.3. Others
• 11.5. Market Value Forecast, by End-user, 2017-2031
  • 11.5.1. Hospitals
  • 11.5.2. Diagnostic Centers
  • 11.5.3. Others (academics & research institutes, etc.)
• 11.6. Market Value Forecast, by Country, 2017-2031
  • 11.6.1. U.S.
  • 11.6.2. Canada
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Flu Virus Type
  • 11.7.2. By Test Type
  • 11.7.3. By Product Type
  • 11.7.4. By End-user
  • 11.7.5. By Country

12. Europe Influenza Diagnostics Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Flu Virus Type, 2017-2031
  • 12.2.1. Type A
  • 12.2.2. Type B
• 12.3. Market Value Forecast, by Test Type, 2017-2031
  • 12.3.1. RT-PCR Tests
  • 12.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
  • 12.3.3. Viral Culture
  • 12.3.4. Immunofluorescence Assays
  • 12.3.5. Serological Tests
  • 12.3.6. Others (LAMP, SAMBA, etc.)
• 12.4. Market Value Forecast, by Product Type, 2017-2031
  • 12.4.1. Kits & Reagents
  • 12.4.2. Instrument
  • 12.4.3. Others
• 12.5. Market Value Forecast, by End-user, 2017-2031
  • 12.5.1. Hospitals
  • 12.5.2. Diagnostic Centers
  • 12.5.3. Others (academics & research institutes, etc.)
• 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.6.1. Germany
  • 12.6.2. U.K.
  • 12.6.3. France
  • 12.6.4. Spain
  • 12.6.5. Italy
  • 12.6.6. Rest of Europe
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Flu Virus Type
  • 12.7.2. By Test Type
  • 12.7.3. By Product Type
  • 12.7.4. By End-user
  • 12.7.5. By Country/Sub-region

13. Asia Pacific Influenza Diagnostics Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Flu Virus Type, 2017-2031
  • 13.2.1. Type A
  • 13.2.2. Type B
• 13.3. Market Value Forecast, by Test Type, 2017-2031
  • 13.3.1. RT-PCR Tests
  • 13.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
  • 13.3.3. Viral Culture
  • 13.3.4. Immunofluorescence Assays
  • 13.3.5. Serological Tests
  • 13.3.6. Others (LAMP, SAMBA, etc.)
• 13.4. Market Value Forecast, by Product Type, 2017-2031
  • 13.4.1. Kits & Reagents
  • 13.4.2. Instrument
  • 13.4.3. Others
• 13.5. Market Value Forecast, by End-user, 2017-2031
  • 13.5.1. Hospitals
  • 13.5.2. Diagnostic Centers
  • 13.5.3. Others (academics & research institutes, etc.)
• 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.6.1. China
  • 13.6.2. Japan
  • 13.6.3. India
  • 13.6.4. Australia & New Zealand
  • 13.6.5. Rest of Asia Pacific
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Flu Virus Type
  • 13.7.2. By Test Type
  • 13.7.3. By Product Type
  • 13.7.4. By End-user
  • 13.7.5. By Country/Sub-region

14. Latin America Influenza Diagnostics Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Flu Virus Type, 2017-2031
  • 14.2.1. Type A
  • 14.2.2. Type B
• 14.3. Market Value Forecast, by Test Type, 2017-2031
  • 14.3.1. RT-PCR Tests
  • 14.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
  • 14.3.3. Viral Culture
  • 14.3.4. Immunofluorescence Assays
  • 14.3.5. Serological Tests
  • 14.3.6. Others (LAMP, SAMBA, etc.)
• 14.4. Market Value Forecast, by Product Type, 2017-2031
  • 14.4.1. Kits & Reagents
  • 14.4.2. Instrument
  • 14.4.3. Others
• 14.5. Market Value Forecast, by End-user, 2017-2031
  • 14.5.1. Hospitals
  • 14.5.2. Diagnostic Centers
  • 14.5.3. Others (academics & research institutes, etc.)
• 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.6.1. Brazil
  • 14.6.2. Mexico
  • 14.6.3. Rest of Latin America
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Flu Virus Type
  • 14.7.2. By Test Type
  • 14.7.3. By Product Type
  • 14.7.4. By End-user
  • 14.7.5. By Country/Sub-region

15. Middle East & Africa Influenza Diagnostics Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Flu Virus Type, 2017-2031
  • 15.2.1. Type A
  • 15.2.2. Type B
• 15.3. Market Value Forecast, by Test Type, 2017-2031
  • 15.3.1. RT-PCR Tests
  • 15.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
  • 15.3.3. Viral Culture
  • 15.3.4. Immunofluorescence Assays
  • 15.3.5. Serological Tests
  • 15.3.6. Others (LAMP, SAMBA, etc.)
• 15.4. Market Value Forecast, by Product Type, 2017-2031
  • 15.4.1. Kits & Reagents
  • 15.4.2. Instrument
  • 15.4.3. Others
• 15.5. Market Value Forecast, by End-user, 2017-2031
  • 15.5.1. Hospitals
  • 15.5.2. Diagnostic Centers
  • 15.5.3. Others (academics & research institutes, etc.)
• 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 15.6.1. GCC Countries
  • 15.6.2. South Africa
  • 15.6.3. Rest of Middle East & Africa
• 15.7. Market Attractiveness Analysis
  • 15.7.1. By Flu Virus Type
  • 15.7.2. By Test Type
  • 15.7.3. By Product Type
  • 15.7.4. By End-user
  • 15.7.5. By Country/Sub-region

16. Competition Landscape

• 16.1. Market Player - Competition Matrix (by tier and size of companies)
• 16.2. Market Share Analysis, by Company (2022)
• 16.3. Company Profiles
  • 16.3.1. 3M
    • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.1.2. Product Portfolio
    • 16.3.1.3. Financial Overview
    • 16.3.1.4. SWOT Analysis
    • 16.3.1.5. Strategic Overview
  • 16.3.2. Abbott
    • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.2.2. Product Portfolio
    • 16.3.2.3. Financial Overview
    • 16.3.2.4. SWOT Analysis
    • 16.3.2.5. Strategic Overview
  • 16.3.3. F. Hoffmann-La Roche Ltd.
    • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.3.2. Product Portfolio
    • 16.3.3.3. Financial Overview
    • 16.3.3.4. SWOT Analysis
    • 16.3.3.5. Strategic Overview
  • 16.3.4. Becton, Dickinson and Company
    • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.4.2. Product Portfolio
    • 16.3.4.3. Financial Overview
    • 16.3.4.4. SWOT Analysis
    • 16.3.4.5. Strategic Overview
  • 16.3.5. BIOMERIEUX
    • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.5.2. Product Portfolio
    • 16.3.5.3. Financial Overview
    • 16.3.5.4. SWOT Analysis
    • 16.3.5.5. Strategic Overview
  • 16.3.6. Bio-Rad Laboratories, Inc.
    • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.6.2. Product Portfolio
    • 16.3.6.3. Financial Overview
    • 16.3.6.4. SWOT Analysis
    • 16.3.6.5. Strategic Overview
  • 16.3.7. Goldsite Diagnostics Inc.
    • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.7.2. Product Portfolio
    • 16.3.7.3. Financial Overview
    • 16.3.7.4. SWOT Analysis
    • 16.3.7.5. Strategic Overview
  • 16.3.8. Hologic, Inc.
    • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.8.2. Product Portfolio
    • 16.3.8.3. Financial Overview
    • 16.3.8.4. SWOT Analysis
    • 16.3.8.5. Strategic Overview
  • 16.3.9. DiaSorin S.p.A.
    • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.9.2. Product Portfolio
    • 16.3.9.3. Financial Overview
    • 16.3.9.4. SWOT Analysis
    • 16.3.9.5. Strategic Overview
  • 16.3.10. Meridian Bioscience, Inc.
    • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.10.2. Product Portfolio
    • 16.3.10.3. Financial Overview
    • 16.3.10.4. SWOT Analysis
    • 16.3.10.5. Strategic Overview
  • 16.3.11. QuidelOrtho Corporation
    • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.11.2. Product Portfolio
    • 16.3.11.3. Financial Overview
    • 16.3.11.4. SWOT Analysis
    • 16.3.11.5. Strategic Overview
  • 16.3.12. SA Scientific Ltd.
    • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.12.2. Product Portfolio
    • 16.3.12.3. Financial Overview
    • 16.3.12.4. SWOT Analysis
    • 16.3.12.5. Strategic Overview
  • 16.3.13. Sekisui Diagnostics
    • 16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.13.2. Product Portfolio
    • 16.3.13.3. Financial Overview
    • 16.3.13.4. SWOT Analysis
    • 16.3.13.5. Strategic Overview
  • 16.3.14. Siemens Healthineers
    • 16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.14.2. Product Portfolio
    • 16.3.14.3. Financial Overview
    • 16.3.14.4. SWOT Analysis
    • 16.3.14.5. Strategic Overview
  • 16.3.15. Thermo Fisher Scientific
    • 16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.15.2. Product Portfolio
    • 16.3.15.3. Financial Overview
    • 16.3.15.4. SWOT Analysis
    • 16.3.15.5. Strategic Overview